- Home
- JLL vs GMAB Comparison
JLL vs GMAB Comparison
Compare JLL & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | GMAB |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | Denmark |
| Employees | 48000 | 3088 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6B | 16.5B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | JLL | GMAB |
|---|---|---|
| Price | $325.45 | $28.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $365.33 | $39.56 |
| AVG Volume (30 Days) | 362.1K | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | ★ $26,115,600,000.00 | N/A |
| Revenue This Year | $7.71 | $17.85 |
| Revenue Next Year | $6.99 | $16.04 |
| P/E Ratio | $95.91 | ★ $1.90 |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $259.83 | $21.00 |
| 52 Week High | $363.06 | $35.43 |
Technical Indicators
Market Signals| Indicator | JLL | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 56.59 | 60.32 |
| Support Level | $313.65 | $28.07 |
| Resistance Level | $337.45 | $29.70 |
| Average True Range (ATR) | 9.63 | 0.71 |
| MACD | -0.79 | -0.06 |
| Stochastic Oscillator | 51.52 | 58.91 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $86 billion for clients across diverse public and private real estate strategies as of the end of 2025.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.